Dendritic cell-tumor fusion vaccine prevents tumor growth in vivo.
Dendritic cells (DCs) are potent antigen presenting cells that are uniquely effective in generating primary immune responses. DCs that are manipulated to present tumor antigens induce antitumor immunity in animal models and preclinical human studies. A myriad of strategies have been developed to load tumor antigen effectively onto DCs. DC-tumor fusion presents a spectrum of tumor-associated antigens to helper T- and cytotoxic T-cell populations in the context of DC-mediated costimulatory signals. In this study, fusion cells (FCs) were generated with MCA-102 fibrosarcoma cells and murine bone marrow-derived myeloid DCs. The FCs coexpressed the DC-derived MHC class II and costimulatory molecules. The FCs also retained the functional properties of DCs and stimulated syngeneic T cell proliferation and interferon-gamma (IFN-gamma) production. Significantly, the results show that syngeneic T cells are primed by FCs to induce MHC class I-dependent lysis of MCA-102 fibrosarcoma. These findings indicate that fusions of tumor cells and DCs activate T-cell responses against syngeneic tumors.
Kim
Gi-Young
GY
Faculty of Applied Marine Science, Cheju National University, South Korea. immunkim@cheju.ac.kr
Chae
Ho-Jin
HJ
Kim
Ki-Hyung
KH
Yoon
Man-Soo
MS
Lee
Kyu-Sub
KS
Lee
Chang-Min
CM
Moon
Dong-Oh
DO
Lee
Jun-Sik
JS
Jeong
Young-Il
YI
Choi
Yung Hyun
YH
Park
Yeong-Min
YM
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D002459:Cell Fusion; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000166:cytology* / Q000276:immunology*; D018450:Disease Progression; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology*; D010641:Phenotype; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D019496:Cancer Vaccines